The combination resulted in a significantly slower tumor growth compared with compound A0317859 or anti-PD-1 alone, which parallels the results of PAK4 KO and KD tumors and provides a new rationale for the combination of PD-1 blockade with a specific PAK4 kinase inhibitor (Fig. 6C). This evidence concerns the gene PAK4 and neoplasm.